Novartis buys Myricx Bio for up to $1.5B
Novartis’ acquisition of Myricx Bio is a major European biotech exit and another sign that large pharma is buying differentiated drug platforms to expand oncology pipelines.
Large pharma is continuing to buy specialised biotech platforms rather than relying only on internal research pipelines.
What happened
Novartis agreed to acquire London-based biotech Myricx Bio for up to $1.5B.
The transaction includes $1.1B upfront and up to $400M in milestone payments. Myricx develops antibody-drug conjugate technology for cancer treatment, and the deal is expected to close in the second half of 2026.
Why it matters
This is a strong biotech exit signal because it shows strategic buyers paying large sums for differentiated platform technology before a company necessarily becomes a huge standalone commercial business.
Antibody-drug conjugates are designed to deliver treatment more selectively to cancer cells, and large pharmaceutical groups are competing to strengthen their capabilities in the area.
The deal also matters for European biotech. A UK company reaching a potential $1.5B acquisition value provides a meaningful validation point for investors backing science-heavy platforms with long development timelines.
The bigger picture
Biotech M&A is increasingly becoming part of the innovation model for large pharma. Startups develop focused technologies, generate early validation and then become acquisition targets for companies with global clinical and commercial infrastructure.
That can make strategic exits as important as IPOs for venture-backed life sciences companies.